Liver Fibrosis Progression and Mortality in Hepatitis B- and C-Coinfected Persons Treated With Directly Acting Antiviral Agents: Results From ERCHIVES. Academic Article uri icon

Overview

abstract

  • For persons with baseline Fibrosis-4 1.46-3.25, cirrhosis incidence/1000 patient-years was 49.3 among hepatitis B virus (HBV)/hepatitis C virus (HCV) coinfected and 18.2 among HCV monoinfected (P = .03). Cirrhosis risk was numerically higher but statistically nonsignificant among HBV/HCV coinfected (hazards ratio [HR] 1.51; 95% confidence intervals [CI], .37-6.05) but lower among those who attained sustained virologic response (HR, .52; 95% CI, .42-.63).

publication date

  • July 27, 2020

Research

keywords

  • Coinfection
  • HIV Infections
  • Hepatitis B
  • Hepatitis C
  • Hepatitis C, Chronic

Identity

PubMed Central ID

  • PMC7530468

Scopus Document Identifier

  • 85079128381

Digital Object Identifier (DOI)

  • 10.1093/cid/ciz1097

PubMed ID

  • 31840746

Additional Document Info

volume

  • 71

issue

  • 3